Evolution of the Pregnane X Receptor: Adaptation to Cross-Species Differences in Biliary Bile Salts

Matthew D. Krasowski, Kazuto Yasuda, Lee R. Hagey and Erin G. Schuetz

Department of Pathology and Committee on Clinical Pharmacology and Pharmacogenomics (M.D.K.), University of Chicago, Chicago, Illinois 60637; Department of Pharmaceutical Sciences (K.Y., E.G.S.), St. Jude Children’s Research Hospital, Memphis, Tennessee 38105; Zoological Society of San Diego (L.R.H.), San Diego, California 92112; and Department of Medicine (L.R.H.), University of California San Diego, San Diego, California 92093

Address all correspondence and requests for reprints to: Matthew D. Krasowski, M.D., Ph.D., University of Pittsburgh, Department of Pathology, 200 Lothrop, Pittsburgh, Pennsylvania 15213. E-mail: kra3{at}uchicago.edum or erin.schuetz{at}stjude.org.


    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 
The pregnane X receptor (PXR) regulates the metabolism and elimination of bile salts, steroids, and xenobiotics. The sequence of the PXR ligand-binding domain diverges extensively between different animals, suggesting interspecies differences in ligands. Of the endogenous ligands known to activate PXR, biliary bile salts vary the most across vertebrate species, ranging from 27-carbon (C27) bile alcohol sulfates (early fish, amphibians) to C24 bile acids (birds, mammals). Using a luciferase-based reporter assay, human PXR was activated by a wide variety of bile salts. In contrast, zebrafish PXR was activated efficiently only by cyprinol sulfate, the major zebrafish bile salt, but not by recent bile acids. Chicken, mouse, rat, and rabbit PXRs were all activated by species-specific bile acids and by early fish bile alcohol sulfates. In addition, phylogenetic analysis using maximum likelihood demonstrated evidence for nonneutral evolution of the PXR ligand-binding domain. PXR activation by bile salts has expanded from narrow specificity for C27 bile alcohol sulfates (early fish) to a broader specificity for recent bile acids (birds, mammals). PXR specificity for bile salts has thus paralleled the increasing complexity of the bile salt synthetic pathway during vertebrate evolution, an unusual example of ligand-receptor coevolution in the nuclear hormone receptor superfamily.


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 
THE PREGNANE X RECEPTOR (PXR; NR1I2), a member of the nuclear hormone receptor (NR) superfamily, is a key regulator of bile salt, steroid hormone, and xenobiotic metabolism and excretion. PXR binds a remarkably diverse array of compounds at low affinity, consistent with its hypothesized role as the initial step in the detoxification of a broad array of toxic compounds (1, 2). Although no high-affinity endogenous ligands for PXR have been identified, pregnane steroids (e.g. the progesterone metabolite 5ß-pregnane-3,20-dione) and bile acids activate PXR at micromolar concentrations (2, 3, 4, 5, 6, 7, 8, 9). Whereas the biological significance of PXR activation by steroid hormones is as yet unclear, the importance of PXR in regulating metabolism of bile acids has been established in mammals. Activation of mammalian PXRs by high concentrations of bile acids, which may accumulate in cholestasis (10), initiates a coordinated metabolic response to eliminate bile acids by increasing expression of metabolic enzymes and bile acid efflux pumps and decreasing expression of enzymes involved in bile acid biosynthesis and uptake (11, 12, 13, 14). The protective role of PXR in regulating metabolism and elimination of toxic bile acids has been elegantly demonstrated in mouse models (4, 15, 16, 17, 18). In contrast, the role of PXR in nonmammalian species is much less understood.

PXR genes have been cloned and functionally characterized from a variety of vertebrate species, including zebrafish, frog, chicken, rat, mouse, rabbit, dog, pig, rhesus monkey, and human (1, 7, 9, 19, 20, 21). PXR has the typical NR organization of an N-terminal DNA-binding domain (DBD) and a C-terminal ligand-binding domain (LBD); however, in comparing PXR sequences between vertebrate species, a striking feature is high cross-species sequence divergence in the LBD. The LBD of PXR shares amino acid identities of only 75% between human and rodent sequences and only 50% between human and chicken or fish sequences. These sequence identities are unusually low when compared with other NRs, for which the corresponding amino acid sequence identities tend to be at least 10–15% higher than the values above (7, 22).

The variation in the LBD of PXR is more striking when DNA sequences are analyzed, in particular by comparing the rate of nonsynonymous (i.e. changes amino acid sequence) and synonymous (does not change amino acid sequence) nucleotide substitution rates. When human and rodent sequences are compared, the LBD of PXR has nonsynonymous substitution rates (dN) 3.7 times higher than the average for all other NRs, even though the synonymous substitution rates (dS) for PXR are average for NRs. The ratios of dN/dS for the PXR are 4 times higher than the average for other NR genes (22). Elevated dN/dS ({omega}) ratios suggest positive natural selection due to the accumulation of advantageous amino acid substitutions (23).

The high sequence divergence of the PXR LBD has been speculated to be an adaptation to xenobiotic ligands (7, 22), although the nature of such ligands is currently unknown. The xenobiotics currently known to activate PXR are all synthetic ligands or herbal products; dietary ligands for PXR have not yet been described. An alternative hypothesis is that cross-species variation in endogenous ligands has influenced PXR evolution (11). Of the endogenous ligands known to activate PXR, biliary bile salts vary the most across vertebrate species (Table 1Go) (24, 25, 26). For example, most mammals produce predominantly 24-carbon (C24) bile acids such as cholic acid and chenodeoxycholic acid, conjugated to either glycine or taurine, from end metabolism of 27-carbon cholesterol. In contrast, cartilaginous fish and many early bony fish typically synthesize C27 bile alcohols, conjugated with sulfate, and, in fact, do not produce C24 bile acids (Table 1Go and Figs. 1Go and 2Go).


View this table:
[in this window]
[in a new window]
 
Table 1. Bile Salts Found in Vertebrates

 


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 1. Chemical Structures of Bile Salts from Various Vertebrate Species

Cholic acid (upper right) is a 24-carbon bile acid typical of those found in birds and mammals. Cholic acid is commonly conjugated to either glycine or taurine (middle right and lower right, respectively). 5{alpha}-Cyprinol (upper left), a penta-hydroxylated bile alcohol, is found in a number of cypriniform fish species (including zebrafish) and was isolated in the current study from carp. This bile alcohol is typically conjugated with sulfate (middle left). The bottom left structure is a long-chain (27-carbon) bile acid isolated from alligator but typical of those found in reptiles and amphibians. Note the long side chain (arrows) on the bile compounds from carp and alligator as compared with cholic acid, the more extensive hydroxylation of 5{alpha}-cyprinol as compared with cholic acid, and the differing orientations of the hydrogen atom at the 5 position between 5{alpha}-cyprinol and 5ß-bile acids. The numbers for 5{alpha}-cyprinol indicate the numbering of the carbon atoms.

 


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 2. Comparative Vertebrate Pathways of Bile Salt Biosynthesis

All bile salts are ultimately derived from end metabolism of 27-carbon cholesterol with 7{alpha}-hydroxylation of cholesterol being the rate-limiting step. The evolutionarily earliest bile salts are 5{alpha}-bile alcohol sulfates, modern-day examples of which are 5{alpha}-cyprinol sulfate in Asiatic carp and 5{alpha}-petromyzonol sulfate in sea lampreys. C27 bile acids are found in reptiles and amphibians; some amphibians such as X. laevis utilize both C27 bile acids and C27 bile alcohol sulfates. Mammals and birds predominantly use C24 bile acids as their biliary bile salts. Primary bile salts are synthesized in the liver whereas secondary bile salts are formed by the action of intestinal bacteria. Usually the predominant bile salts found in the bile are primary bile salts; an exception is the rabbit, for which the secondary bile salt deoxycholic acid is the predominant circulating bile salt.

 
In this study, we use an in vitro assay to examine activation of PXRs from a variety of vertebrate animals by species-specific bile salts, some of which were isolated from natural sources. For comparison, we also study bile salt activation of the vitamin D receptor (VDR; NR1I1), a receptor closely related to PXR that also plays a role in bile salt detoxification. We demonstrate that bile salt activation of PXRs is conserved from teleost fish to mammals, although PXR specificity for bile salts has expanded greatly during vertebrate evolution. In addition, using phylogenetic analysis we provide evidence of nonneutral evolution of the PXR LBD. We propose that evolution of the PXR LBD has been shaped by changes in vertebrate biliary bile salts, an unusual example in the NR superfamily of a receptor adapting to changing endogenous ligands.


    RESULTS
 TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 
Differing Bile Salt Activation Profiles for Human PXR, Zebrafish PXR, and Human VDR
To study bile salt effects on a phylogenetically diverse set of vertebrate PXRs, the zebrafish PXR was chosen for a detailed comparison to human PXR and human VDR. Bony fish are the evolutionarily most distant organisms from mammals from which PXR genes haves been cloned. Any function that is conserved between fish and mammals is likely to be fundamental for PXRs. Also, zebrafish biliary bile salts are quite different from those in mammals and thus provide a critical test to the hypothesis that PXRs are activated by species-specific bile salts. A previous report showed that although some pregnane and androstane steroids activated zebrafish PXR (like mammalian and chicken PXRs), mammalian bile acids such as cholic acid and lithocholic acid did not activate this receptor (7).

The bile salts of many nonmammalian species differ from the typical bile salts found in mammals and are generally commercially unavailable. To allow for the study of these compounds, the following chemically diverse bile salts were isolated from animals by extraction and Flash column chromatography (see Table 2GoGo for chemical formulae): myxinol disulfate from the Atlantic hagfish (Myxine glutinosa); 5{alpha}-cyprinol sulfate from the Asiatic carp (Cyprinus carpio); 5ß-scymnol sulfate from the Spotted eagle ray (Aetobatus narinari); and 3{alpha},7{alpha},12{alpha}-trihydroxy-5ß-cholestan-27-oic acid, taurine conjugated, from the American alligator (Alligator mississippiensis). The isolation and purification of cyprinol and cyprinol sulfate have been previously described in detail (27). Bile alcohol sulfates were chemically deconjugated. Completeness of deconjugation and assessment of purity were performed by thin-layer chromatography using known standards.


View this table:
[in this window]
[in a new window]
 
Table 2. Effects of Bile Salts, Bile Salt Precursors, and Benzoates on Human PXR, Zebrafish PXR, Human VDR, and Mouse VDR

 

View this table:
[in this window]
[in a new window]
 
Table 2A. Continued

 
We used an in vitro assay system in HepG2 human liver cells that allowed for detailed determination of the EC50 and relative efficacy of compounds that induce PXRs or VDRs (see Materials and Methods). Figure 3Go, A and C, shows that, as previously described (7, 8, 28), the mammalian bile acid lithocholic acid activated human PXR and VDR in the micromolar range. This activation had low efficacy relative to that produced by rifampicin and 1,25-(OH)2-vitamin D3, respectively (see Supplemental Table Ia, published as supplemental data on The Endocrine Society’s Journals Online web site at http://mend.endojournals.org, for maximal activators used for each receptor). Lithocholic acid did not activate zebrafish PXR (Fig. 3BGo). In contrast, the major digestive detergent of zebrafish bile, 5{alpha}-cyprinol sulfate, was a robust activator of human and zebrafish PXRs, but not human VDR (Fig. 3Go). None of the three receptors were affected by unconjugated cyprinol, a poorly water-soluble compound that is present in fish mainly as a precursor to the secreted cyprinol sulfate (27). Both lithocholic acid and cyprinol sulfate also activated a GAL4-LBD fusion construct for human PXR. The EC50 values for activation of this fusion construct were similar to those determined for the full-length human PXR; the efficacies of lithocholic acid and cyprinol sulfate relative to rifampicin were higher than seen for the full-length receptor although in either case cyprinol sulfate was more efficacious than lithocholic acid as a human PXR activator (Table 2GoGo). These results indicate that the activation of the human PXR by cyprinol sulfate is a function of the LBD and not of another region of the receptor.



View larger version (18K):
[in this window]
[in a new window]
 
Fig. 3. Concentration-Response Data for Activation of Human PXR, Zebrafish PXR, and Human VDR

The ordinate represents activation of the PXR or VDR, relative to vehicle control, and normalized to the maximal activator [rifampicin for human PXR, 5{alpha}-androstan-3{alpha}-ol for zebrafish PXR, and 1,25-(OH)2-vitamin D3 for human VDR; see supplemental Table Ia]. The drugs tested were rifampicin ({circ}), lithocholic acid (LCA, {bullet}), androstanol ({square}), 5{alpha}-cyprinol sulfate ({blacksquare}), 5{alpha}-cyprinol ({blacktriangleup}), and 1,25-(OH)2-vitamin D3 ({triangleup}). A, Human PXR is activated efficaciously by rifampicin, androstanol, and 5{alpha}-cyprinol sulfate. Micromolar concentrations of lithocholic acid activated human PXR but with low efficacy relative to rifampicin (~{epsilon} = 0.15). Human PXR was not activated by 1,25-(OH)2-vitamin D3 or unconjugated cyprinol. B, Zebrafish PXR is activated efficaciously by micromolar concentrations of androstanol and 5{alpha}-cyprinol sulfate but is not activated by lithocholic acid, unconjugated cyprinol, rifampicin, or 1,25-(OH)2-vitamin D3. C, Human VDR is activated by nanomolar concentrations of 1,25-(OH)2-vitamin D3 and with low efficacy by micromolar concentrations of lithocholic acid. Human VDR is not activated by androstanol, rifampicin, cyprinol sulfate, or unconjugated cyprinol. In panels A and B, full-length receptors for human PXR and VDR were used, with the reporter plasmid being CYP3A4-PXRE-Luc. In panel C, a GAL4-LBD fusion was used for zebrafish PXR, with the reporter plasmid being tk-UAS-Luc.

 
A total of 47 structurally diverse bile salts or bile salt precursors were tested on human PXR, zebrafish PXR, mouse VDR, and human VDR. Human PXR had broad specificity for bile salts, being activated by 25 of the 47 compounds tested (Figs. 3AGo and 4Go and Table 2GoGo). Zebrafish PXR was only activated by four of 47 bile salts tested. In addition to cyprinol sulfate, zebrafish PXR was also activated by 5ß-scymnol sulfate (a C27 hexa-hydroxylated bile alcohol sulfate derived from the Spotted eagle ray, a cartilaginous fish) and lithocholic acid 3-sulfate, indicating a preference for sulfated bile salts; zebrafish PXR was also activated weakly by the synthetic bile acid derivative lithocholic acid acetate. None of the unconjugated bile alcohols, glycine-conjugated bile acids, or taurine-conjugated bile acids tested activated zebrafish PXR (Figs. 3BGo and 4Go and Table 2GoGo). Human and mouse VDRs were activated by a narrow range of bile acids, mainly lithocholic acid and its metabolites or synthetic derivatives, and not by any of the C27 bile acids, sulfated bile alcohols, or unconjugated bile alcohols (Figs. 3CGo and 4Go and Table 2GoGo). Mouse VDR was not activated by specific rodent primary or secondary biliary bile acids including {alpha}-muricholic acid, ß-muricholic acid (unconjugated and taurine conjugated), {omega}-muricholic acid, and murideoxycholic acid (Table 2GoGo).



View larger version (27K):
[in this window]
[in a new window]
 
Fig. 4. Patterns of Bile Salt Activation of PXRs and VDRs

Eight compounds were chosen to encompass the chemical diversity of bile salts and their synthetic precursors across vertebrates. 5ß-Cholestan-3{alpha},7{alpha},12{alpha}-triol ("Triol") is a precursor to all bile salts studied in this report except the 5{alpha}-bile alcohol sulfates and uncommon 5{alpha}-bile acids (e.g. allocholic acid). The alligator C27 bile acid represents taurine-conjugated 3{alpha},7{alpha},12{alpha}-trihydroxy-5ß-cholestan-27-oic acid isolated from bile of the American alligator. CDCA, chenodeoxycholic acid (chicken and mammalian primary bile acid); Muri-DCA, murideoxycholic acid (rodent secondary bile acid); LCA, lithocholic acid (toxic secondary bile acid of birds and mammals). Of the compounds represented, zebrafish PXR was only activated by 5{alpha}-cyprinol sulfate. Frog receptors BXR{alpha}/ß were not activated by any bile salts, consistent with these receptors having diverged from other PXRs to mediate specific developmental roles in amphibians. Chicken and mammalian PXRs are generally broadly activated by bile salts, with each species activated well by its own bile salts. Of the eight compounds depicted, mouse and human VDRs were activated only by lithocholic acid, a toxic secondary bile acid. Lamprey VDR was activated only very weakly by cyprinol [maximal effect ~5% that achieved with 1,25-(OH)2-vitamin D3].

 
Activity of the Sea Lamprey VDR
Recently, a VDR was cloned and functionally expressed from the sea lamprey (Petromyzon marinus), a jawless vertebrate (29). Expression of the full-length sea lamprey cDNA in a mammalian cell line resulted in a product able to transactivate a luciferase construct driven by a promoter containing the distal vitamin D response element from the human CYP3A4 gene; expression was enhanced by cotransfection with a zebrafish retinoic X receptor (RXR) gene (29). In our experiments in HepG2 cells, 1,25-(OH)2-vitamin D3 caused a robust increase in luciferase activity when lamprey VDR cDNA was cotransfected with CYP3A4-PXRE-Luc, a reporter plasmid containing the distal vitamin D response element from the human CYP3A4 gene (supplemental Table Ia). Expression was further enhanced by cotransfection with 10 ng/well of zebrafish RXRß (supplemental Table Ia). All subsequent experiments with lamprey VDR were thus performed with cotransfected zebrafish RXRß.

Although the lamprey VDR was activated well by 1,25-(OH)2-vitamin D3, no other compounds tested were able to activate this receptor to more than 10% of the maximal response achieved with 300 nM 1,25-(OH)2-vitamin D3. Unlike the mouse and human VDRs, recent bile acids, particularly lithocholic acid, did not activate the lamprey VDR (supplemental Table Ib). Several early bile salts, such as petromyzonol sulfate, 3-ketopetromyzonol sulfate, and cyprinol sulfate, produced weak but concentration-dependent and reproducible increases in reporter activity; however, for all three compounds, the maximal effects were only less than 5–6% of the maximal effect seen with 300 nM 1,25-(OH)2-vitamin D3. The EC50 value for activation of the lamprey VDR by petromyzonol sulfate and 3-ketopetromyzonol sulfate was approximately 1 µM whereas that for cyprinol sulfate was approximately 20 µM (supplemental Table Ib). The small effects produced by these bile alcohol sulfates require correlation with in vivo findings in sea lampreys.

Activation of Other Vertebrate PXRs by Bile Salts
Rats and mice have a similar bile acid profile although they use slightly different primary bile acids ({alpha}- and ß-muricholic acid, respectively; Table 1Go and Fig. 2Go). PXRs from both rodents were activated by micromolar concentrations of murideoxycholic acid (the secondary bile acid metabolite formed by bacterial 7-dehydroxylation of {alpha}- or ß-muricholic acids), lithocholic acid, and {alpha}-muricholic acid (Table 3Go and Fig. 4Go).


View this table:
[in this window]
[in a new window]
 
Table 3. Effects of Bile Acids, Bile Acid Precursors, Cyprinol Sulfate, Scymnol Sulfate, and Two Steroids on Mouse and Rat PXRs

 
Rabbits have an atypical circulating bile salt pool consisting mainly of deoxycholic acid. As in other mammals, deoxycholic acid is a secondary bile acid formed in the rabbit intestine by bacterial 7-dehydroxylation of primary bile acids such as chenodeoxycholic acid (30). For most mammalian species, however, deoxycholic acid is quite toxic and represents only a small fraction of the bile acid pool; in the rabbit, deoxycholic acid is more than 95% of the circulating bile acids. Rabbit PXR was activated efficaciously in the midmicromolar range by deoxycholic acid, glycodeoxycholic acid, taurodeoxycholic acid, and 7-ketodeoxycholic acid, and in general was activated by a variety of diverse bile salts (Table 4Go and Fig. 4Go).


View this table:
[in this window]
[in a new window]
 
Table 4. Effects of Bile Acids, Cyprinol Sulfate, Scymnol Sulfate, and Bile Acid Precursors on Rabbit and Chicken PXRs

 
The main primary bile acids in chickens are chenodeoxycholic acid and cholic acid (Table 1Go and Fig. 2Go). The chicken PXR was activated by chenodeoxycholic acid, glycochenodeoxycholic acid, cholic acid, and lithocholic acid in the micromolar range (Table 4Go and Fig. 4Go).

Interestingly, chicken, mouse, rabbit, rat, and human PXRs were all activated by 5{alpha}-cyprinol sulfate and 5ß-scymnol sulfate, bile alcohol sulfates derived from carp and skate bile, respectively (Figs. 3AGo and 4Go and Tables 2–4GoGoGoGo). Because these or similar bile salts are not the major bile salts of chickens, rabbits, mice, rats, or humans (although they can be found in trace amounts in healthy animals or in higher levels in certain disease states; see Discussion), activation by these compounds likely represents an ancestral property conserved in chicken and mammalian PXRs.

Benzoate X Receptors (BXR{alpha} and BXRß) Are Insensitive to All Bile Salts
Bile from Xenopus laevis frogs and some other amphibians contain a mixture of C27 bile alcohols and bile acids (Hagey, L. R., unpublished data) (24, 25, 26). In this study, we tested a variety of bile alcohol sulfates, unconjugated bile alcohols, and bile salts, including myxinol disulfate (from hagfish), cyprinol sulfate (from carp), scymnol sulfate (from skate), petromyzonol sulfate (from sea lamprey), and taurine-conjugated 3{alpha},7{alpha},12{alpha}-trihydroxy-5ß-cholestan-27-oic acid (from alligator; same as the C27 bile acid found in X. laevis), on BXR{alpha} and BXRß. None of these compounds activated BXR{alpha} or BXRß (supplemental Table Ic and Fig. 4Go), suggesting that these receptors do not play a role in sensing bile salts. As previously reported (21), benzoate compounds robustly activated these two receptors (supplemental Table Ic).

The effects of five benzoate compounds on zebrafish, chicken, and mammalian PXRs have been previously reported (7). Interestingly, two of the benzoate compounds (n-butyl-p-aminobenzoate and n-propyl-p-hydroxybenzoate) tested by Moore et al. (7) activated a number of the PXRs. The endogenous benzoate isolated by Blumberg et al. (21) from X. laevis embryos, 3-aminoethylbenzoate, however, only activated chicken PXR in addition to BXR{alpha} (7). We confirmed the sensitivity of human PXR to n-butyl-p- aminobenzoate and also show activation of zebrafish PXR by n-propyl-p-hydroxybenzoate (Table 2GoGo). In contrast, n-butyl-p-aminobenzoate, n-propyl-p-aminobenzoate, and 3-aminoethylbenzoate all did not activate human, mouse, or lamprey VDRs (Tables 2GoGo and 4Go and supplemental Table Ib).

Activation of PXRs by the Bile Salt Precursor 5ß-Cholestan-3{alpha},7{alpha},12{alpha}-triol
The bile salt biosynthetic pathways for all of the vertebrates considered in this study except zebrafish include 5ß-bile alcohol precursors (zebrafish use an early 5{alpha}-bile alcohol pathway). One of these precursors is 5ß-cholestan-3{alpha},7{alpha},12{alpha}-triol, a compound that accumulates in the rare disease cerebrotendinous xanthomatosis (OMIM accession no. 213700), an inborn error of metabolism caused by deficiency of CYP27A1. In humans, CYP27A1 deficiency leads to pathological accumulations of C27 bile alcohols and the hallmark symptoms of cerebrotendinous xanthomatosis, namely xanthomas, gallstones, and neurological dysfunction (31).

Tables 2–4GoGoGoGo show that whereas human and zebrafish PXRs were not activated by 5ß-cholestan-3{alpha},7{alpha},12{alpha}-triol, mouse, rabbit, rat, and chicken PXRs were all activated by low micromolar concentrations of this bile alcohol. Rat and mouse PXRs were activated particularly efficaciously by this bile alcohol (Table 3Go), as previously described for the mouse PXR (3, 4). BXR{alpha} and BXRß were not activated by 5ß-cholestan-3{alpha},7{alpha},12{alpha}-triol (supplemental Table Ic). The lack of activation of zebrafish PXR by 5ß-cholestan-3{alpha},7{alpha},12{alpha}-triol may be a result of these fish utilizing the earlier 5{alpha}-bile alcohol biosynthetic pathway also found in jawless fish; as a result, 5ß-cholestan-3{alpha},7{alpha},12{alpha}-triol is not an intermediate in the synthesis of 5{alpha}-cyprinol sulfate, the major zebrafish bile salt (27). None of the PXRs or VDRs were activated by 7{alpha}-hydroxycholesterol, the earliest precursor in the biotransformation of cholesterol to bile salts (Tables 2–4GoGoGoGo).

The lack of activation of human PXR by the bile salt precursor 5ß-cholestan-3{alpha},7{alpha},12{alpha}-triol detected in the transactivation assay is consistent with previous data by Dussault et al. (3) showing that 5ß-cholestan-3{alpha},7{alpha},12{alpha}-triol is a very low efficacy partial agonist of human PXR. In that report, 5ß-cholestan-3{alpha},7{alpha},12{alpha}-triol weakly transactivated a human PXR construct but was unable to induce CYP3A4 mRNA expression in primary human hepatocytes; 5ß-cholestan-3{alpha},7{alpha},12{alpha}-triol did, however, competitively displace [3H]SR12813 from binding to human PXR, demonstrating that this bile alcohol does bind to human PXR (3). The significance of the lack of efficacy for 5ß-cholestan-3{alpha},7{alpha},12{alpha}-triol for activating human PXR is uncertain, although it may be of interest that studies with primary human hepatocytes show that this bile alcohol precursor is practically nonexistent in the formation of bile acids such as cholic or chenodeoxycholic acid, a finding that contrasts with the previously assumed pathways of bile acid biosynthesis in humans (32). Comparative studies in other species have not been performed to study whether this finding is unique to humans or common throughout mammals.

Evidence for Nonneutral Evolution of the PXR LBD
Previous phylogenetic investigations of PXR genes have only looked at two-sequence comparisons in calculating dN/dS ({omega}) ratios: one study focused on human, mouse, and rat sequences (22) and the other on human, chimpanzee, and mouse sequences (33). Table 5Go shows the results from phylogenetic analysis by maximum likelihood (PAML) analysis of sequence data for PXR and VDR genes. A total of six analyses were performed for each gene: full-length sequence, restricted to DBD, and restricted to LBD for datasets of either all available vertebrate species or mammals only.


View this table:
[in this window]
[in a new window]
 
Table 5. Statistically Superior PAML Models from Analysis of Sequence Data from the PXR and VDR Genes

 
The analyses for the full-length sequence, DBD, and LBD for VDR, whether applied to all available species or mammals only, show low {omega}-ratios, consistent with purifying (negative) selection as the dominant evolutionary force for this gene. The PXR analyses, on the other hand, for the full-length sequence and LBD show a minority of codons (sites) with {omega}-ratios approaching or even exceeding 1 (results in bold in Table 5Go). In contrast, the {omega}-ratios for the DBD are low for the PXR analyses. These results are consistent with positive selection acting on the PXR LBD.

The analysis for the LBD of PXR restricted to mammalian species, in which 7% of codons were associated with an {omega}-ratio of 1.23, also highlighted four amino acid residues as likely targets of positive selection: 187S, 231S (H1–H3 insert), 312A (helix 6), and 360R (helix 9) [amino acid numbers for human PXR as in Moore et al., (7); complete sequence alignment of the LBD of VDRs and PXRs available as supplemental Fig. 1 published as supplemental data on The Endocrine Society’s Journals Online web site at http://mend.endojournals.org). Posterior probabilities for the positive selection of the individual codon sites are greater than 0.99 for 360R and 0.90–0.98 for 187S, 231S, and 312A.

We also used PAML to detect whether evidence of molecular adaptation occurs along specific lineages. With regard to ligand specificity, the most divergent of the PXRs are clearly the BXRs (Fig. 5Go). If the assignment of BXR{alpha} and BXRß as true orthologs of other PXRs is correct, then these receptors have lost the ability to respond to endogenous steroids and bile salts and also the broad specificity required to bind structurally diverse xenobiotics. Using a PAML model that allows for two discrete classes of {omega} for all sequences in a phylogeny and an additional class of {omega} for defined lineage(s), (model B of Ref. 34 ; see Materials and Methods for more details), we analyzed the entire set of available PXRs. For the full-length, DBD-only, and LBD-only sequences, we separately analyzed four specific sets of lineages for positive selection: the branch from all other PXRs to the BXRs (branch a of Fig. 5Go), the branch to BXR{alpha} (branch b of Fig. 5Go), the branch to BXRß (branch c of Fig. 5Go), and branches a, b, c together.



View larger version (21K):
[in this window]
[in a new window]
 
Fig. 5. Hypothetical Phylogeny of PXRs and VDRs Showing Functional Characteristics

The phylogenetic tree is based on known phylogenetic relationships between the species. Features included are activation by endogenous compounds (bile acids, bile alcohol sulfates, androstane steroids, pregnane steroids, 1,25-(OH)2-vitamin D3, and benzoates) and xenobiotics [pregnenolone 16{alpha}-carbonitrile (PCN), rifampicin]. The organization is one possible arrangement and may change with sequence data in additional species. Branches a, b, and c indicate specific branches of the phylogeny tested in the phylogenetic analysis by maximum likelihood (see Results and supplemental Table II). LCA, Lithocholic acid; Vit. D3, vitamin D3; esp., especially.

 
We find evidence for positive selection in individual branches a, b, and c (supplemental Table II published as supplemental data on The Endocrine Society’s Journals Online web site at http://mend.endojournals.org). The amino acid residues identified as likely targets of positive selection are all in the LBD (supplemental Fig. 1 and supplemental Table II). Three of the residues identified correspond to residues in human PXR shown to directly interact with ligand in the two crystal structures of the human PXR LBD complexed with ligand (35, 36). This suggests that if indeed BXRs are orthologs of other PXRs, then sequence changes that altered the ligand specificity and response of an ancestral PXR have been positively selected for in amphibian evolution.


    DISCUSSION
 TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 
Activation of PXRs by Species-Specific Bile Salts Is Conserved across Vertebrates
The major finding of this study is that activation of PXR by bile salts is conserved across vertebrates, from teleost fish to mammals, an evolutionary time span of more than 400 million years. A previous study had shown no activation by bile salts in zebrafish PXR but only tested mammalian-type C24 bile acids (7). The exception to the general sensitivity of PXRs to bile salts is found in the frog. X. laevis, PXRs, the benzoate X receptors (BXRs), exhibit pharmacological properties and tissue expression patterns markedly different from other PXRs (see below) (7, 21, 37).

PXR activation by bile salts parallels the evolution of complexity of the bile salt biosynthetic pathway. Unlike most forms of evolution, bile salt evolution has proceeded by elongation of an enzyme pathway. This long pathway is now shared by different hepatic organelles, with its start in the mitochondria, steroid ring modification in the endoplasmic reticulum and cytoplasm, and side-chain modifications in the peroxisomes (38). Jawless fish, cartilaginous fish, and some bony fish (e.g. zebrafish) utilize relatively simple bile alcohol pathways that generally leave the side chain of cholesterol intact. The insensitivity of zebrafish PXR to recent 5ß-bile acids is perhaps not surprising, as these fish would never encounter such compounds (nor would their ancestors). PXR activation by bile salts has thus expanded from narrow specificity for C27 bile alcohol sulfates (early fish pattern) to a broader specificity for recent bile acids and their synthetic precursors (birds and mammals). PXR selectivity for bile salts has therefore paralleled the elongation and increasing complexity of the bile salt synthetic pathway during vertebrate evolution.

The evolution of the bile salt biosynthesis pathway and its relation to PXR evolution contrasts with that for the classical steroid hormones and their cognate receptors. In a detailed analysis of the vertebrate NR3 family (estrogen, androgen, progesterone, glucocorticoid, and mineralocorticoid receptors), Thornton (39) has proposed that "... the terminal ligand in a biosynthetic pathway is the first for which a receptor evolves; selection for this hormone also selects for the synthesis of intermediates despite the absence of receptors, and duplicated receptors then evolve affinity for these substances." Thornton also concluded that the estrogen receptor was likely the most ancient classical steroid receptor (39), an idea supported by an elegant reconstruction and functional expression of the ancestral estrogen receptor (40). The bile salt biosynthetic pathway has evolved in a considerably different fashion from the adrenocortical and sex steroid pathways, starting off from a relatively simple pathway to produce C27 bile alcohol sulfates and steadily elongating to a more complex pathway that results in the production of C24 bile acids. Therefore, the evolution of PXR in mammals and birds has adapted not to the intermediate products of bile salt biosynthesis but to the species-specific, specialized, terminal products of a biosynthetic pathway elongating over evolutionary time.

Biliary bile salts show a striking amount of diversity between different vertebrate species (24, 25). This contrasts with hormones or neurotransmitters, which tend to be well conserved (41). The PXRs have adapted to cross-species variation in bile composition. The zebrafish PXR has narrow selectivity toward bile salts, being activated by only two sulfated bile alcohols, one sulfated bile acid, and one synthetic bile acid derivative out of a panel of 47 bile compounds tested. The most efficacious activation of zebrafish PXR was by its dominant bile detergent, 5{alpha}-cyprinol sulfate. In contrast, mammalian PXRs, in particular human and rabbit PXRs, are activated efficaciously by a wide variety of bile acids (conjugated or unconjugated) and sulfated bile alcohols. Rat and mice PXRs are activated efficaciously by {alpha}-muricholic acid as well as murideoxycholic acid, the secondary bile acid of rodent {alpha}- and ß-muricholic acids. In contrast, murideoxycholic acid does not activate PXRs from humans or chickens, two species in which this bile acid would not be present. This suggests that PXRs have adapted to subtle species-specific differences in bile salt biosynthesis and metabolism.

An unexpected finding was that all PXRs except frog BXRs were activated by 5{alpha}-cyprinol sulfate and 5ß-scymnol sulfate. The most ancient vertebrates, hagfish and lampreys (jawless fish), utilize 5{alpha}-bile alcohol sulfates similar to cyprinol sulfate as their major bile detergents; these compounds are assumed to be the first class of bile detergents synthesized by ancestral vertebrates (42, 43). Consequently, activation of PXR by the earliest bile constituents, 5{alpha}-bile alcohol sulfates, is an ancestral property conserved in comparatively recent fish (like zebrafish), birds, and mammals. This pattern of conservation is remarkable considering the extensive divergence between the LBDs of zebrafish and mammalian PXRs (only 50% amino acid sequence identity) and the more than 400 million years of time since the last common ancestor of tetrapods and telost fish (44).

Interestingly, even though C24 bile acids are the dominant digestive detergents of most mammals, low concentrations of 5ß-cyprinol or similar C27 bile alcohols are found in humans and other mammals (45, 46, 47). This is a reflection of the evolution of the bile salt biosynthetic pathway described above, in which the synthesis of a recent bile acid such as cholic acid results from extra processing and enzymatic steps added onto the basic pathway that produces C27 bile alcohols (38). As a result, all mammals produce some C27 bile alcohols, although the efficiency of conversion to C24 bile acids in healthy animals normally reduces bile alcohols to trace levels. Detailed analysis of urinary bile alcohols in healthy humans reveals a range of bile alcohols including 5ß-cyprinol; in patients with cholestasis and certain inborn errors of bile metabolism, levels of urinary bile alcohols can rise dramatically (46, 48). In addition, a small number of mammals including elephants and rock hyraxes produce C27 bile alcohol sulfates as their only bile detergents; in essence, these mammals have retained the basic bile detergent synthetic pathway found in ancestral fishes (24, 25). The persistence of C27 bile alcohols even in healthy animals and their elevation in certain disease states may provide some selective advantage for mammalian PXRs to maintain their ancestral sensitivity to early bile salts such as cyprinol sulfate and scymnol sulfate.

Physiological Importance of Bile Salt Activation of Vertebrate PXRs
Detection of bile salts by PXR may not simply be a mechanism to increase removal of bile salts but part of a more general protective mechanism. In fact, with a few exceptions (e.g. lithocholic acid), bile salts are not highly toxic compounds (49). However, elevated intrahepatic levels of bile acids are a sentinel marker of cholestasis and herald impaired biliary elimination of other toxic compounds. Activation of PXRs by abnormally high bile salt concentrations would be beneficial by inducing alternative routes of metabolism and elimination of toxins normally cleared in the bile.

Lithocholic acid activated chicken PXR and all mammalian PXRs. Numerous studies have demonstrated the toxicity of this mono-hydroxylated, secondary bile acid, generated by bacterial 7-dehydroxylation of primary bile acids such as chenodeoxycholic acid in the intestine (49). Lithocholic acid and its metabolites were also activators of mouse and human VDRs, as previously reported (28). For animals using C24 bile acids such as chenodeoxycholic acid, mechanisms to detect and reduce the toxicity of lithocholic acid would be advantageous. In the case of mammals, two related NRs, PXR and VDR, both detect lithocholic acid and activate pathways to detoxify this compound (28, 49). The studies with sea lamprey VDR show that activation by lithocholic acid and its derivatives is not a conserved property of all VDRs.

Whereas the physiological importance of PXR activation by bile acids in mammals has been demonstrated, the situation is less clear in nonmammalian species. The metabolism and toxicology of fish bile salts has been little studied, and the genes affected by PXR activation in fish have not been defined. 5{alpha}-Cyprinol sulfate, the bile detergent of zebrafish and other cypriniform fish (e.g. carp, goldfish, zebrafish), is quite toxic to a number of mammals (27, 50), including humans, and can cause renal and hepatic failure in individuals who ingest raw goldfish or carp gallbladders (51), a delicacy in East Asia.

Relation of PXR Activation to Physiologically Relevant Bile Salt Concentrations
The concentrations of species-specific bile salts that activate the vertebrate PXRs in this study are within the range encountered in disease affecting the hepatobiliary system. In healthy humans, plasma concentrations of bile acids are generally low micromolar (see Materials and Methods). In subjects with cholestasis from a variety of etiologies, plasma bile acid concentrations can rise dramatically and exceed 100 µM, well within the levels that activate human PXR (10).

Plasma concentrations of bile acids in healthy chickens, mice, rats, and rabbits are similar to humans, with normal total plasma bile acid concentrations generally in the low micromolar range (see Materials and Methods). The concentrations required to activate PXRs in these species are generally about 1 order of magnitude or more higher than would be seen in healthy animals and would be encountered in animals with hepatobiliary disorders such as cholestasis. As in humans, diseases affecting the hepatobiliary systems can dramatically elevate plasma bile acid concentrations in other animals. Concentrations of plasma bile acids exceeding 1 mM have been achieved in experimental animals, such as in mice following bile duct ligation (52). Unfortunately, at the present time, intrahepatocyte or plasma concentrations of bile salts, or their degree of binding to plasma proteins, have not been reported for fish or amphibians.

Lack of Activation of Frog BXRs by Bile Salts
BXR{alpha} and BXRß, the putative PXRs from X. laevis, are clearly different from other vertebrate PXRs. Although the complete genome of X. laevis has not yet been sequenced (leaving open the possibility of discovering additional PXR-like genes), sequence similarity and phylogeny strongly support the classification of these receptors as PXRs (7, 37, 53). Nevertheless, the tissue distribution and functional properties of these receptors are quite different from other PXRs. For example, BXRs are highly expressed in ovary and testis but poorly expressed in xenobiotic metabolizing organs such as liver, lung, or kidney (37). BXR{alpha} and BXRß do not appear to function as xenobiotic sensors, and previous reports have shown these receptors to be insensitive to a wide range of steroidal compounds (7, 21, 37). The present study finds these two receptors to be completely insensitive to amphibian bile salts. BXR{alpha} and BXRß are both activated well by benzoates, compounds that have unique roles in frog development (21). Assuming that these two receptors are indeed orthologous to other PXRs, they have evidently diverged extensively to perform specific benzoate-mediated developmental functions in frogs (21, 37).

In this report, we confirmed the findings of Moore et al. (7) that certain benzoate compounds activate a variety of PXRs other than the BXRs, including those from zebrafish, chicken, and human, and also show that activation by benzoates is not shared by human, mouse, or lamprey VDRs. The significance of activation of PXRs other than BXR{alpha} and BXRß by synthetic benzoates is unknown; physiological actions of this class of endogenous compounds has only been described in amphibians (21, 37). Even if benzoates do not have a physiological role in modern-day fish, birds, or mammals, it is possible that ancestors to these species may have used benzoate compounds and, thus, that sensitivity to these compounds is a shared ancestral trait of PXRs. Alternatively, low-affinity activation of nonamphibian PXRs by benzoates, compounds with low molecular weight relative to other PXR ligands, may simply be a consequence of the broad specificity of PXRs and may not have physiological or evolutionary significance. BXRs have not been cloned and characterized from any species other than X. laevis (21, 37). Whether receptors similar to the Xenopus BXRs exist in other amphibians (e.g. the salamander axolotl), reptiles, or any other species remains to be discovered. Complete sequencing of the Xenopus genome and of other species will be critical in determining whether BXRs are indeed orthologous to other PXRs and also whether amphibians have PXR-like xenobiotic receptors that have not yet been identified.

Evolution of the NR1I Subfamily of Nuclear Hormone Receptors
The NR1I subfamily includes VDR (NR1I1), PXR (NR1I2), and the constitutive androstane receptor (CAR; NR1I3) (6, 7, 54). VDR and PXR are found in diverse vertebrates from bony fish to mammals. CAR, on the other hand, appears restricted to mammals, although there is some uncertainty in classifying the chicken PXR, as this receptor has about equal sequence and functional similarity to both PXRs and CARs (7, 20). Recent evidence suggests that the CAR gene arose from a duplication of a premammalian PXR gene (55). This is consistent with the demonstration of two xenobiotic-responsive NRs in mammals, but only one in chickens and fish (53, 55). The complete genome of the fugu fish contains a single PXR gene and shows no evidence for a CAR gene (53).

Based on current genetic data, distinct NR1I subfamily members have been found only in vertebrates. A VDR was cloned and functionally expressed from the sea lamprey (P. marinus), a surprising finding as this jawless vertebrate lacks calcified tissue (29). PXR has not yet been identified in jawless vertebrates, and our attempts to clone a PXR gene from the sea lamprey have been unsuccessful. The draft genome of the urochordate Ciona intestinalis, the closest invertebrate relative of vertebrates for which complete genome information is available, revealed a single NR gene equally related to VDR and a Drosophila NR (56). The functional properties of this invertebrate NR remain uncharacterized.

An excellent study of the evolutionary genomics of the NR superfamily provides convincing evidence that a single ancestral NR duplicated and diverged to form VDR and PXR. This paper also proposes that the NR complement in the ancestor to Bilateria (animals) possessed nine genes in the NR1 family (57). Thus, distinct PXR and VDR genes are likely vertebrate innovations although complete genome information is not yet available for a cephalochordate such as amphioxus, an invertebrate chordate more closely related to vertebrates than Ciona.

Figure 5Go shows a hypothetical phylogenetic tree of the NR1I subfamily that incorporates functional characteristics of the subfamily members. Pharmacological features shown are activation by endogenous compounds [bile acids, bile alcohol sulfates, steroid hormones, benzoates, and 1,25-(OH)2-vitamin D3] and xenobiotics (pregnenolone 16{alpha}-carbonitrile, rifampicin). Figure 5Go shows the progressive broadening of ligand specificity for the PXRs, with human, dog, and pig PXRs having the broadest ligand specificity, at least for the ligands that have been tested to date (7).

Several reports have suggested that the most ancient function of the NR1I family is to recognize toxic levels of exogenous and/or endogenous compounds (7, 11, 28, 29). The detoxification function of VDR in humans has only been recently recognized and is exemplified by the ability of VDR to sense toxic levels of lithocholic acid in the intestine and up-regulate metabolic enzymes to detoxify this secondary bile acid (17, 28). A further description of the NR1I subfamily origins awaits complete genome information in jawless fish and cephalochordates and functional characterization of the NR1I subfamily members in these organisms, if present.

Structural Basis for Differing Ligand Selectivities between the PXRs
The mechanism of ligand activation of human PXR has been demonstrated by high-resolution, crystallographic, three-dimensional structures of the LBD alone (35) and in combination with the hypocholesterolemic compound SR12813 (35, 58), hyperforin (active component of St. John’s wort) (36), or the human steroid receptor coactivator-1 (SRC-1) (58). The human PXR LBD shares structural features with other NR LBDs, including an {alpha}-helical sandwich of helices {alpha}1/{alpha}3, {alpha}4/{alpha}5/{alpha}8, and {alpha}7/{alpha}10 in one hemisphere of the molecule and the ligand-binding cavity in the other hemisphere (35, 59). The human PXR ligand-binding cavity is smooth, hydrophobic, and large (1150 Å3), second in size for NRs only to peroxisome proliferator-activated receptor-{gamma} (1500 Å3) (60). This is in contrast to most NRs, which have a compact ligand-binding cavity that closely resembles the shape of their specific ligand(s) (59). There is also considerable flexibility in the human PXR ligand-binding cavity, which increases in size by 250 Å3 following binding of hyperforin (36). There are a number of additional features of the human PXR LBD that contribute to its broad ligand specificity: a variable four-residue turn between helices {alpha}1 and {alpha}3, replacement of {alpha}6 by a large, flexible loop, and two additional ß-strands not observed in other NRs (35, 36, 58, 59).

A total of 18 amino acid residues in the human PXR LBD have been identified as contacting either SR12813, hyperforin, or both (see supplemental Fig. 1 for sequence alignments and highlighting of ligand-binding residues); one residue contacts hyperforin only and five residues contact SR12813 only (35, 36). No three-dimensional structures of human PXR bound to an endogenous ligand have been reported. The generally low affinity of these compounds may make this difficult to achieve. In comparing human and zebrafish PXR sequences, 12 of the 18 amino acid residues identified in binding SR12813 and/or hyperforin differ between the two sequences, in some cases dramatically (supplemental Fig. 1, A and B). In fact, alignment of human PXR, chicken PXR, BXR{alpha}, BXRß, and zebrafish PXR shows that only three of these 18 ligand-contacting amino acid residues are completely conserved among these five sequences (supplemental Fig. 1B). A combination of molecular modeling and site-directed mutagenesis will probably be required to elucidate the structural basis of ligand selectivity differences between these PXRs.

Contrasting Levels of PXR Nucleotide Diversity within Humans and between Vertebrates
The marked diversity of the PXR LBD between vertebrate species contrasts with a detailed resequencing study of the human PXR gene that showed very low nucleotide diversity and no nonsynonymous substitutions in the PXR LBD in genomic DNA of approximately 100 individuals from diverse ethnic populations. The total nucleotide diversity was 1 in 21,607 bp for the LBD and 1 in 22,053 for the DBD (61). This low level of nucleotide diversity within humans differs markedly with the high levels of divergence of PXR genes between vertebrate species. This suggests that important ligand(s) for PXR do not vary significantly across human populations but do vary across vertebrate species. We propose biliary bile salts as a group of endogenous ligands that fit this qualification.

In summary, this study shows that activation by species-specific bile salts is a conserved property of PXRs from teleost fish to mammals and that recognizing high concentrations of bile salts is likely an ancestral function of PXRs. More strikingly, the specificity of PXRs to bile salts has expanded during vertebrate evolution, mirroring the complex evolution of bile salt biosynthetic pathways across vertebrate species. Given evidence for positive selection acting on the PXR LBD, we propose that differences in biliary bile salts between vertebrate species have been a selective force for PXR evolution.


    MATERIALS AND METHODS
 TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 
Isolation of Bile Salts from Natural Sources
Commercially unavailable bile salts were obtained by extraction and Flash column chromatography using bile from natural sources in which a single major bile salt predominates. The protocol had been approved by the Committee on Animal Studies of the University of California, San Diego. Bile salts isolated (see Table 2GoGo for chemical formulae) were: myxinol disulfate from the Atlantic hagfish (M. glutinosa); 5{alpha}-cyprinol sulfate from the Asiatic carp (C. carpio); 5ß-scymnol sulfate from the Spotted eagle ray (A. narinari); and 3{alpha},7{alpha},12{alpha}-trihydroxy-5ß-cholestan-27-oic acid, taurine conjugated, from the American alligator (A. mississippiensis). The isolation and purification of cyprinol and cyprinol sulfate have been previously described in detail (27). Bile alcohol sulfates were deconjugated using a solution of 2,2-dimethoxypropane-1.0 N HCl, 7:1 (vol/vol), and incubating 2 h at 37 C, followed by the addition of water and extraction into ether. Completeness of deconjugation and assessment of purity was performed by thin-layer chromatography using known standards.

Reagents
The sources of the chemicals were as follows: rifampicin, n-propyl-4-hydroxybenzoate, n-butyl-4-aminobenzoate, pregnenolone 16{alpha}-carbonitrile, nifedipine, 1,25-(OH)2-vitamin D3, glycocholic acid, taurocholic acid, glycodeoxycholic acid, taurodeoxycholic acid, lithocholic acid 3-sulfate, taurolithocholic acid 3-sulfate, and glycolithocholic acid 3-sulfate (Sigma Chemical Co., St. Louis, MO); 5{alpha}-petromyzonol, petromyzonol sulfate, 3-ketopetromyzonol, 3-ketopetromyzonol sulfate, 3-keto-7{alpha},12{alpha}-dihydro-5{alpha}-cholanic acid, and allocholic acid (Toronto Research Chemicals, Inc., North York, Ontario, Canada). All other bile salts, as well as 5{alpha}-androstan-3{alpha}-ol and 5ß-pregnane-3,20-dione, were obtained from Steraloids (Newport, RI).

Construction of HepG2 Cell Line Stably Expressing Human Na+-Taurocholate Transporter (hNTCP)
HepG2 (human liver) cell lines stably expressing hNTCP (62), which is required for effective uptake of conjugated bile compounds into cells, were used for the transactivation experiments. To construct this line, hNTCP cDNA was subcloned into pcDNA3. HepG2 cells (104 cells per P60 dish, plated on d 1) were transfected on d 2 by calcium phosphate coprecipitation with 5 µg of pcDNA3-hNTCP plasmid. HepG2 cells stably transfected with pcDNA3-hNTCP were grown in MEM-{alpha} medium (Invitrogen, Carlsbad, CA) containing 10% fetal bovine serum and 1% penicillin/streptomycin. The HepG2-hNTCP cells were grown under selective pressure with 1000 µg/ml G418. The cell lines were grown at 37 C in 5% CO2.

To determine the hNTCP expression, RNA was isolated from HepG2-hNTCP cells using Trizol reagent (Invitrogen). Total RNA (5 µg) was reverse transcribed according to instructions. Primers used to amplify were 5'-gggacatgaacctcagcatt-3' (forward) and 5'-cgtttggatttgaggacgat-3' (reverse). PCRs contained 1 µl of cDNA, 5 pmol of primers, 1.5 mmol MgCl2, 0.2 mmol deoxynucleotide triphosphates, and 2.5 U of Taq polymerase (Promega Corp., Madison, WI). PCR consisted of an initial denaturation at 92 C for 5 min followed by 34 cycles of denaturation at 92 C for 30 sec, annealing at 60 C for 30 sec, and synthesis at 72 C for 30 sec, with a final extension at 72 C for 10 min.

Transactivation Assays and Cell Culture
Plasmids containing cDNAs for eight PXRs from seven species [human, mouse, rat, rabbit, chicken (chicken PxR), frog (BXR{alpha} and BXRß), zebrafish], human vitamin D receptor (VDR; NR1I1), human Na+-taurocholate cotransporter (NTCP; SLC10A1), human organic anion transporting polypeptide (SLC21), as well as the reporter constructs tk-UAS-Luc and CYP3A4-PXRE-Luc, and empty vectors pCDNA, pSG5, and PM2 were generously provided by S. A. Kliewer, J. T. Moore, and L. B. Moore (GlaxoSmithKline, Research Triangle Park, NC). The sea lamprey VDR clone (the insertless full-length cDNA) was generously provided by G. K. Whitfield (University of Arizona College of Medicine, Tucson, AZ) (29). Mouse VDR (IMAGE clone 3710866) and pCMV-sport6 vectors were obtained from Invitrogen. The zebrafish RXRß cDNA clone (IMAGE clone 5410111) was obtained from ATCC (Manassas, VA). The expression vectors were either full-length receptors (i.e. containing both a DBD and LBD; human, mouse, rat, rabbit, and chicken PXRs, as well as human, mouse, and sea lamprey VDRs) or GAL4/PXR chimeras that contain only the LBD of the PXR (human SXR, BXR{alpha}, BXRß, and zebrafish PXR) (7). For the full-length expression vectors, the reporter plasmid was CYP3A4-PXRE-Luc, a construct that contains a promoter element from CYP3A4 (recognized by PXR and VDR DBDs) driving luciferase expression. For the GAL4/LBD expression constructs, the reporter plasmid was tk-UAS-Luc, which contains GAL4 DNA binding elements driving luciferase expression. The sea lamprey VDR cDNA was cotransfected with zebrafish RXRß (15 ng/well) for more robust expression.

It should be pointed out that cross-species differences in the DBDs of various PXRs could impact the ability of a particular PXR to activate the human CYP3A4-based promoter driving luciferase expression. However, this is unlikely to affect the pharmacology of the various ligands studied in this report, particularly as ligand activation of a particular receptor was normalized to a specific maximal activator. The most distantly related PXRs to the human PXR, zebrafish PXR and the frog BXRs, were studied using GAL4-LBD fusion constructs; therefore, issues of cross-species differences in the DBD do not affect those receptors in this study. Also, the transactivation assays used will not detect compounds that bind to PXRs but do not transactivate (or transactivate very poorly). Other than for human PXR, suitable radioligands for other PXRs have not yet been developed.

The cell line used for the assays was HepG2 (human liver) cells stably expressing human NTCP, a transporter that can uptake conjugated bile acids. For experiments involving sulfated compounds, human organic anion transporting polypeptide was cotransfected at 10 ng/well to facilitate uptake of sulfated steroids or bile salts. On d 1, 30,000 cells per well were seeded onto 96-well white opaque plates (Corning-Costar, Corning, NY). On d 2, cells were transfected using the calcium phosphate precipitation method with expression vector or empty control vector and luciferase reporter plasmid. On d 3, the cells were washed and then incubated with medium containing charcoal-dextran-treated fetal bovine serum (Hyclone Laboratories, Inc., Logan, UT) and drugs or vehicle. On d 4, the cells were washed and the medium replaced with serum-free medium. Luciferase reagent with passive lysis buffer (Steady-Glo, Promega Corp.) was added. Two hours later, luminescence was measured in a 96-well luminometer (Analyst AD, Molecular Devices, Sunnyvale, CA). An aliquot of lysed cells was taken to measure total protein content (RC DC Protein Assay; Bio-Rad Laboratories, Inc., Hercules, CA). Experiments were performed in quadruplicate and repeated for a total of at least three times.

Activation of receptor by ligand was compared with receptor exposed to identical conditions without ligand (vehicle control). In general, dimethyl sulfoxide (Sigma) was used as vehicle and was adjusted to be 1% (vol/vol) in all wells. A control was also run with transfection of empty vector (i.e. lacking the receptor cDNA) and reporter vector to control for activation of reporter vector by endogenous receptor(s). In experiments with a variety of activators, activation by endogenous receptors was not seen. Concentration-response curves were fitted using Kaleidagraph software (Synergy Software, Reading, PA). Data are presented throughout as mean ± SEM. In combining data from multiple experiments, the pooled variance was calculated by the formula spooled = {[(n1 – 1)s12 + (n2 – 1)s22 + ... + (nk – 1)sk2]/[N – k]}–1/2, where there are N total data points among k groups, with n replicates in the ith group.

Determination of Maximal Activators for the Various PXRs
Using previous comparative studies of vertebrate PXRs as a guide (6, 7), each PXR construct was tested with compounds previously shown to be robust activators of the respective receptors. Supplemental Table Ia shows the receptors tested, the type of reporter construct used, the amount of reporter construct and receptor cDNA transfected per well, and the activation of luciferase activity, relative to vehicle control, produced by a maximal activator. As can be seen, maximal induction of luciferase activity varies over almost 2 orders of magnitude. This is a result of differing levels of baseline (constitutive) activation and intrinsic differences in receptor properties. Mouse and chicken PXRs show high levels of constitutive activation and low maximal activation by ligand; in contrast, human VDR, mouse VDR, BXR{alpha}, BXRß, and zebrafish PXR have low levels of constitutive activity and show greater than 10-fold maximal activation (6, 7, 20, 21, 37). This variability in activation makes it difficult to perform cross-species comparisons of differences in ligand efficacy.

To facilitate more reliable cross-species comparisons, complete concentration-response curves for ligands were determined in the same microplate as determination of response to a maximal activator. This allows for determination of relative efficacy, {epsilon}, defined as the maximal response to test ligand divided by the maximal response to a reference maximal activator (note than {epsilon} can exceed 1). Compounds with {epsilon} less than 0.10 were designated "inactive." The maximal activators and concentrations eliciting maximal response are listed in supplemental Table Ia. Figure 3Go shows concentration-response curves for human PXR, zebrafish PXR, and human VDR. The ordinate represents activation of the PXR or VDR, relative to vehicle control, and normalized to the maximal activator. For the human PXR data in Fig. 3AGo, rifampicin is the reference maximal activator (and hence has {epsilon} = 1.0 by definition) whereas lithocholic acid has lower relative efficacy (~{epsilon} = 0.15). Similarly, 5{alpha}-androstan-3{alpha}-ol and 1,25-(OH)2-vitamin D3 are the reference maximal compounds for zebrafish PXR and human VDR in Fig. 3Go, B and C, respectively.

Plasma or Serum Concentrations of Bile Salts in Vertebrates
Circulating total serum concentrations of deoxycholic acid, chenodeoxycholic acid, and cholic acid in humans are 0.23–0.89 µM, 0–1.61 µM, and 0.08–0.91 µM, respectively (63). Total serum bile acids exceed 100 µM in patients with severe cholestasis (10). Bile acids are bound tightly to plasma proteins (~70–95%); therefore, the corresponding free plasma bile acid concentrations will be lower than the values above (64, 65, 66).

Total bile acid concentrations in Sprague Dawley rat plasma are 8.26 ± 6.13 nmol/100 g body weight (67). With rats weighing approximately 400 g and assuming an estimated plasma volume of 5 ml/100 g body weight (68), this corresponds to 0.413 ± 0.31 µM total bile acid concentration in plasma. Concentration of total bile acids in mouse plasma is slightly higher than that in rats (52). Similarly, total bile acid concentrations in New Zealand rabbit plasma were 1.08 ± 0.44 nmol/100 g body weight (67). With rabbits weighing approximately 2000 g and assuming an estimated plasma volume of 20 ml/100 g body weight (69), this corresponds to 0.0027 ± 0.0011 µM. Total bile acid concentrations in hens are 0.075–0.15 µM (70). Concentrations of bile salts in fish or amphibian plasma or serum have not been reported.

Phylogenetic Analysis
Sequences were aligned with Clustal X. Estimation of dN/dS ({omega}) ratios was carried out by maximum likelihood using a codon-based substitution model in PAML (Phylogenetic Analysis by Maximum Likelihood) version 3.13 (71). The input to PAML is a tree file of the phylogeny of the sequences to be studied and a file with aligned sequences. The phylogeny is based on the known phylogenetic relationships between the species to be studied, determined by a consensus of morphological and molecular data (44).

PAML can determine estimates of {omega} for models of varying complexity. The most commonly applied models are as follows (the PAML model numbers are shown in parentheses; the "sites" refers to codons) (72, 73): model M0 (null model with a single {omega}-ratio among all sites), M3 (discrete model, with two or more categories of sites with the {omega}-ratio free to vary for each site), M7 (ß-model, 10 categories of sites, with 10 {omega}-ratios in the range 0–1 taken from a discrete approximation of the ß- distribution), and M8 (ß + {omega} model, 10 categories of sites from a ß- distribution as in M7 plus an additional category of sites with an {omega}-ratio that is free to vary from 0 to >1). PAML estimates the {omega}-ratios that are allowed to vary under these models, as well as the proportion of sites (codons) with each ratio. We also used a combined branch-site model (model B of Ref. 34) in PAML to test for positive selection in specific lineages of the phylogeny. This model allows for a branch or branches of a phylogeny to be selected as foreground and the remaining branches as background. Model B is compared statistically to the simpler model of M3 with two site classes and no selection of specific lineages.

Of the PAML models listed above, only M3 and M8 can detect positive selection (i.e. {omega} > 1). Each PAML model generates a log likelihood, indicating how well the models fit the input data. Some PAML models are nested within each other (e.g. M0 within M3, M7 within M8). In those cases, twice the log likelihood difference between the two models is compared with a {chi}2 distribution with degrees of freedom equal to the difference in degrees of freedom between the two models. P values for sites potentially under positive selection are obtained using a Bayesian approach in PAML (34). The accuracy and power of PAML models increase with more sequences and longer length sequences (74). Simpler PAML models are preferred unless a more complex model fits the observed data significantly better. Analysis was performed on publicly available PXR and VDR coding sequences, either from cDNA sequences or predicted from genomic DNA sequences. VDR was chosen for comparison as the gene most closely related to PXR for which sequence data are available in mammals and other vertebrates (CAR is found only in mammals). Separate PAML analyses were performed on data sets of full-length sequence and restricted to either DBD or LBD, the two major domains of NRs, and to data sets consisting of all available vertebrate species and restricted to mammals only. Mammalian and fish PXRs have an approximately 40-amino acid insertion domain between LBD helices 1 and 3 (termed "H1–H3 insert") although there is little sequence similarity between mammalian and fish sequences (7, 53). The H1–H3 insert is absent in X. laevis BXR{alpha} and BXRß (21) and only partially present in chicken PXR (20). The H1–H3 insert sequence was excluded in PAML analyses that include both mammalian and nonmammalian PXR genes due to uncertainties in alignment and lack of sequence for some PXRs.

For PXR, full-length sequence data are available for 11 genes from 10 species (accession numbers in parentheses; unless otherwise specified accession numbers are from GenBank): fugu (SINFRUG76306; http://genome.jgi-psi.org/fugu3/fugu3), zebrafish (AF454673 and AF502918), X. laevis BXR{alpha} (BC041187) and BXRß (AF305201), chicken PxR (AF276753), mouse (AF031814), rat (AF151377), rabbit (AF188476), rhesus monkey (AF454671), chimpanzee (Nov. 2003 chimpanzee Arachne assembly, National Center for Biotechnology Information Build 1 version 1, University of California, Santa Cruz: panTro1), and human (NM_003889). PAML analyses of full-length sequence and DBD are of the above 11 sequences (five mammals). Partial sequence essentially containing only the LBD is available for dog (AF454670) and pig (AF454672); this allows for PAML analysis of the LBD of PXRs to include 13 sequences total (seven mammals).

For VDR, full-length sequence data are available for 11 species: sea lamprey (AY249863), fugu (SINFRUG63876; http://genome.jgi-psi.org/fugu3/fugu3), zebrafish (NM_130919), bastard halibut (AB037674), X. laevis (U91846), chicken (AF011356), Japanese quail (U12641), mouse (NM_009504), rat (NM_017058), cotton-top tamarin monkey (AF354232), and human (NM_000376). PAML analyses of full-length sequence and DBD are of the above 11 sequences (four mammals). Partial sequence covering the DBD is available for the chimpanzee (Nov. 2003 chimpanzee Arachne assembly, NCBI Build 1 version 1, UCSC: panTro1); this allows for PAML analysis of the DBD of VDRs to include 12 sequences total (five mammals).


    ACKNOWLEDGMENTS
 
We thank Dr. Anna Di Rienzo (University of Chicago, Department of Human Genetics, Chicago, IL) for hosting M.D.K. in her laboratory and for helpful discussions. We thank Dr. Alan F. Hofmann for critical reading of the manuscript; S. A. Kliewer, J. T. Moore, and L. B. Moore (GlaxoSmithKline, Research Triangle Park, NC) for providing plasmids; G. K. Whitfield (University of Arizona College of Medicine, Tucson, AZ) for supplying the sea lamprey VDR clone; and the excellent technical assistance of C. Kline (St. Jude Children’s Research Hospital, Memphis, TN).


    FOOTNOTES
 
This work was supported by an internal grant from the University of Chicago Department of Pathology (Vinay Kumar, MD, chairman) and a Robert Priest Fellowship (to M.D.K.). L.R.H. was supported by funding from the Zoological Society of San Diego, San Diego, CA. E.G.S. was supported by National Institute of Health Grants GM60346 and P30 CA21765 Cancer Center Support grant, by the National Institutes of Health/National Institute of General Medical Sciences Pharmacogenetics Research Network and Database (U01 GM61374, http://pharmgkb.org) under grant U01 GM61393, and by American Lebanese Syrian Associated Charities (ALSAC).

First Published Online February 17, 2005

Abbreviations: BXR, Benzoate X receptor; CAR, constitutive androstane receptor; DBD, DNA-binding domain; LBD, ligand-binding domain; NR, nuclear hormone receptor; NTCP, Na+-taurocholate transporter; PAML, phylogenetic analysis by maximum likelihood; PXR, pregnane X receptor; RXR, retinoic X receptor; VDR, vitamin D receptor.

Received for publication October 20, 2004. Accepted for publication February 11, 2005.


    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 

  1. Bertilsson G, Heidrich J, Svensson K, Asman M, Jendeberg L, Sydow-Backman M, Ohlsson R, Postlind H, Blomquist P, Berkenstram A 1998 Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci USA 95:12208–12213[Abstract/Free Full Text]
  2. Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA 1998 The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 102:1016–1023[Abstract/Free Full Text]
  3. Dussault I, Yoo H-D, Lin M, Fan M, Batta AK, Salen G, Erickson SK, Forman BM 2003 Identification of an endogenous ligand that activates pregnane X receptor-mediated sterol clearance. Proc Natl Acad Sci USA 100:833–838[Abstract/Free Full Text]
  4. Goodwin B, Gauthier KC, Umetani M, Watson MA, Lochansky MI, Collins JL, Leitersdorf E, Mangelsdorf DJ, Kliewer SA, Repa JJ 2003 Identification of bile acid precursors as endogenous ligands for the nuclear xenobiotic pregnane X receptor. Proc Natl Acad Sci USA 100:223–228[Abstract/Free Full Text]
  5. Jones SA, Moore LB, Shenk JL, Wisely GB, Hamilton GA, McKee DD, Tomkinson NCO, LeCluyse EL, Lambert MH, Willson TM, Kliewer SA, Moore JT 2000 The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. Mol Endocrinol 14:27–39[Abstract/Free Full Text]
  6. Moore LB, Parks DJ, Jones SA, Bledsoe RK, Consler TG, Stimmel JB, Goodwin B, Liddle C, Blanchard SG, Willson TM, Collins JL, Kliewer SA 2000 Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. J Biol Chem 275:15122–15127[Abstract/Free Full Text]
  7. Moore LB, Maglich JM, McKee DD, Wisely B, Willson TM, Kliewer SA, Lambert MH, Moore JT 2002 Pregnane X receptor (PXR), constitutive androstane receptor (CAR), and benzoate X receptor (BXR) define three pharmacologically distinct classes of nuclear receptors. Mol Endocrinol 16:977–986[Abstract/Free Full Text]
  8. Staudinger JL, Goodwin B, Jones SA, Hawkins-Brown D, MacKenzie KI, LaTour A, Liu Y, Klaassen CD, Brown KK, Reinhard J, Willson TM, Koller BH, Kliewer SA 2001 The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci USA 98:3369–3374[Abstract/Free Full Text]
  9. Blumberg B, Sabbagh W, Juguilon H, Bolado J, van Meter CM, Ong ES, Evans RM 1998 SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev 12:3195–3205[Abstract/Free Full Text]
  10. Fischer S, Beuers U, Spengler U, Zwiebel FM, Koebe H-G 1996 Hepatic levels of bile acids in end-stage chronic cholestatic liver disease. Clin Chim Acta 251:173–186[CrossRef][Medline]
  11. Schuetz EG, Strom S, Yasuda K, Lecureur V, Assem M, Brimer C, Lamba J, Kim RB, Ramachandran V, Komoroski BJ, Venkataramanan R, Cai H, Sinal CJ, Gonzalez FJ, Schuetz JD 2001 Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450. J Biol Chem 276:39411–39418[Abstract/Free Full Text]
  12. Maglich JM, Stoltz CM, Goodwin B, Hawkins-Brown D, Moore JT, Kliewer SA 2002 Nuclear pregnane X receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic distribution. Mol Pharmacol 62:638–646[Abstract/Free Full Text]
  13. Hartley DP, Dai X, He YD, Carlini EJ, Wang B, Huskey SW, Ulrich RG, Rushmore TH, Evers R, Evans DC 2004 Activators of the rat pregnane X receptor differentially modulate hepatic and intestinal gene expression. Mol Pharmacol 65:1159–1171[Abstract/Free Full Text]
  14. Teng S, Jekerle V, Piquette-Miller M 2003 Induction of ABCC3 (MRP3) by pregnane X receptor. Drug Metab Dispos 31:1296–1299[Abstract/Free Full Text]
  15. Zhang J, Huang W, Qatanani M, Evans RM, Moore DD 2004 The constitutive androstane receptor and pregnane X receptor function coordinately to prevent bile acid-induced hepatotoxicity. J Biol Chem 279:49517–49522[Abstract/Free Full Text]
  16. Staudinger J, Liu Y, Mada A, Habeebu S, Klaassen CD 2001 Coordinate regulation of xenobiotic and bile acid homeostasis by pregnane X receptor. Drug Metab Dispos 29:1467–1472[Abstract/Free Full Text]
  17. Xie W, Radominska-Pandya A, Shi Y, Simon CM, Nelson MC, Ong ES, Waxman DJ, Evans RM 2001 An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids. Proc Natl Acad Sci USA 98:3375–3380[Abstract/Free Full Text]
  18. Guo GL, Lambert G, Negishi M, Ward JM, Brewer HB, Kliewer SA, Gonzalez FJ, Sinal CJ 2003 Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity. J Biol Chem 278:45062–45071[Abstract/Free Full Text]
  19. Kliewer SA, Moore JT, Wade L, Staudinger JL, Watson MA, Jones SA, McKee DD, Oliver BB, Willson TM, Zetterstrom RH, Perlmann T, Lehmann JM 1998 An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 92:73–82[CrossRef][Medline]
  20. Handschin C, Podvinec M, Meyer UA 2000 CXR, a chicken xenobiotic-sensing orphan nuclear receptor, is related to both mammalian pregnane X receptor (PXR) and constitutive androstane receptor (CAR). Proc Natl Acad Sci USA 97:10769–10774[Abstract/Free Full Text]
  21. Blumberg B, Kang H, Bolado J, Chen H, Craig AG, Moreno TA, Umesano K, Perlmann T, De Robertis EM, Evans RM 1998 BXR, an embryonic orphan nuclear receptor activated by a novel class of endogenous benzoate metabolites. Genes Dev 12:1269–1277[Abstract/Free Full Text]
  22. Zhang Z, Burch PE, Cooney AJ, Lanz RB, Pereira FA, Wu J, Gibbs RA, Weinstock G, Wheeler DA 2004 Genomic analysis of the nuclear receptor family: new insights into structure, regulation, and evolution from the rat genome. Genome Res 14:580–590[Abstract/Free Full Text]
  23. Yang Z, Bielawski JP 2000 Statistical methods for detecting molecular adaptation. Trends Ecol Evol 15:496–503[CrossRef][Medline]
  24. Hagey LR 1992 Bile acid biodiversity in vertebrates: chemistry and evolutionary implications. Physiology and pharmacology, PhD thesis, University of California, San Diego
  25. Hofmann AF, Schteingart CD, Hagey LR 1995 Species differences in bile acid metabolism. In: Paumgartner G, Beuers U, eds. International Falk Symposium: Bile acids in liver diseases. Dordrecht, The Netherlands: Kluwer Academic Publishers; 3–30
  26. Une M, Hoshita T 1994 Natural occurrence and chemical synthesis of bile alcohols, higher bile acids, and short side chain bile acids. Hiroshima J Med Sci 43:37–67[Medline]
  27. Goto T, Holzinger F, Hagey LR, Cerrè C, Ton-Nu H-T, Schteingart CD, Steinbach JH, Shneider BL, Hofmann AF 2003 Physicochemical and physiological properties of 5{alpha}-cyprinol sulfate, the toxic bile salt of cyprinid fish. J Lipid Res 44:1643–1651[Abstract/Free Full Text]
  28. Makishima M, Lu TT, Xie W, Whitfield GK, Domoto H, Evans RM, Haussler MR, Mangelsdorf DJ 2002 Vitamin D receptor as an intestinal bile acid sensor. Science 296:1313–1316[Abstract/Free Full Text]
  29. Whitfield GK, Dang HTL, Schluter SF, Bernstein RM, Bunag T, Manzon LA, Hsieh G, Dominguez CE, Youson JH, Haussler MR, Marchalonis JJ 2003 Cloning of a functional vitamin D receptor from the lamprey (Petromyzon marinus), an ancient vertebrate lacking a calcified skeleton and teeth. Endocrinology 144:2704–2716[Abstract/Free Full Text]
  30. Hofmann AF, Mosbach EH, Sweeley CC 1969 Bile acid composition of bile from germ-free rabbits. Biochim Biophys Acta 176:204–207[Medline]
  31. Cali JJ, Hsieh C-L, Francke U, Russell DW 1991 Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis. J Biol Chem 266:7779–7783[Abstract/Free Full Text]
  32. Axelson M, Ellis E, Mörk B, Garmark K, Abrahamsson A, Björkhem I, Ericzon B-G, Einarsson C 2000 Bile acid synthesis in culture human hepatocytes: support for an alternative biosynthetic pathway to cholic acid. Hepatology 31:1305–1312[CrossRef][Medline]
  33. Clark AG, Glanowski S, Nielsen R, Thomas PD, Kejariwal A, Todd MA, Tanenbaum DM, Civello D, Lu F, Murphy B, Ferriera S, Wang G, Zheng X, White TJ, Sninsky JJ, Adams MD, Cargill M 2003 Inferring nonneutral evolution from human-chimp-mouse orthologous gene trios. Science 302:1960–1963[Abstract/Free Full Text]
  34. Yang Z 1998 Likelihood ratio tests for detecting positive selection and application to primate lysozyme evolution. Mol Biol Evol 15:568–573[Abstract]
  35. Watkins RE, Wisely GB, Moore LB, Collins JL, Lambert MH, Williams SP, Willson TM, Kliewer SA, Redinbo MR 2001 The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. Science 292:2329–2333[Abstract/Free Full Text]
  36. Watkins RE, Maglich JM, Moore LB, Wisely GB, Noble SM, Davis-Searles PR, Lambert MH, Kliewer SA, Redinbo MR 2003 2.1 Å crystal structure of human PXR in complex with the St. John’s wort compound hyperforin. Biochemistry 42:1430–1438[CrossRef][Medline]
  37. Grün F, Venkatesan RN, Tabb MM, Zhou C, Cao J, Hemmati D, Blumberg B 2002 Benzoate X receptors {alpha} and ß are pharmacologically distinct and do not function as xenobiotic receptors. J Biol Chem 277:43691–43697[Abstract/Free Full Text]
  38. Russell DW 2003 The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem 72:137–174[CrossRef][Medline]
  39. Thornton JW 2001 Evolution of vertebrate steroid receptors from an ancestral estrogen receptor by ligand exploitation and serial genome expansions. Proc Natl Acad Sci USA 98:5671–5676[Abstract/Free Full Text]
  40. Thornton JW, Need E, Crews D 2003 Resurrecting the ancestral steroid receptor: ancient origin of estrogen signaling. Science 301:1714–1717[Abstract/Free Full Text]
  41. Bentley PJ 1998 Comparative vertebrate endocrinology, 3rd ed. Cambridge, UK: Cambridge University Press
  42. Haslewood GAD 1966 Comparative studies of bile salts. Myxinol disulphate, the principal bile salt of hagfish (Myxinidae). Biochem J 100:233–237[Medline]
  43. Haslewood GAD, Tökés L 1969 Comparative studies of bile salts: bile salts of the lamprey Petromyzon marinus L. Biochem J 114:179–184[Medline]
  44. Carroll RL 1988 Vertebrate paleontology and evolution. New York: Freeman
  45. Nakagawa M, Une M, Takenaka S, Kuramoto T, Abukawa D, Iinuma K 1999 Urinary bile alcohol profile in infants with intrahepatic cholestasis: identification of 5ß-cholestane-3{alpha},7{alpha},24,25-tetrol. Acta Paediatr 88:1078–1082[CrossRef][Medline]
  46. Yousef IM, Perwalz S, Lamireau T, Tuchweber B 2003 Urinary bile acid profile in children with inborn errors of bile acid metabolism and chronic cholestasis; screening technique using Electrospray tandem mass-spectrometry (ES/MS/MS). Med Sci Monit 9:MT21–MT31
  47. Ichimiya H, Yanagisawa J, Nakayama F 1984 Significance of bile alcohol in urine of a patient with cholestasis: identification of 5ß-cholestane-3{alpha},7{alpha},12{alpha},26,27-pentol (5ß-cyprinol) and 5ß-cholestane-3{alpha},7{alpha},12{alpha},26-tetrol (27-deoxy-5ß-cyprinol). Chem Pharm Bull (Tokyo) 32:2874–2877[Medline]
  48. Nakagawa M, Une M, Takenaka S, Tazawa Y, Nozaki S, Imanaka T, Kuramoto T 2001 Urinary bile acid profiles in healthy and cholestatic children. Clin Chim Acta 314:101–106[CrossRef][Medline]
  49. Hofmann AF 2004 Detoxification of lithocholic acid, a toxic bile acid: relevance to drug hepatotoxicity. Drug Metab Rev 36:703–722[CrossRef][Medline]
  50. Yeh YH, Wang DY, Deng JF, Chen SK, Hwang DF 2002 Short-term toxicity of grass carp bile powder, 5{alpha}-cyprinol and 5{alpha}-cyprinol sulfate in rats. Comp Biochem Physiol 131:1–8[CrossRef]
  51. Xuan BH, Thi TX, Nguyen ST, Goldfarb DS, Stokes MB, Rabenou RA 2003 Ichthyotoxic ARF after fish gallbladder ingestion: a large case series from Vietnam. Am J Kidney Dis 41:220–224[CrossRef][Medline]
  52. Meerman L, Koopen NR, Bloks V, Van Goor H, Havinga R, Wolthers BG, Kramer W, Stengelin S, Müller M, Kuipers F, Jansen PLM 1999 Biliary fibrosis associated with altered bile composition in a mouse model of erythropoietic protoporphyria. Gastroenterology 117:696–705[Medline]
  53. Maglich JM, Caravella JA, Lambert MH, Willson TM, Moore JT, Ramamurthy L 2003 The first completed genome sequence from a telost fish (Fugu rubripes) adds significant diversity to the nuclear receptor superfamily. Nucleic Acids Res 31:4051–4058[Abstract/Free Full Text]
  54. Forman BM, Tzameli I, Choi H-S, Chen J, Simha D, Seol W, Evans RM, Moore DD 1998 Androstane metabolites bind to and deactivate the nuclear receptor CAR-ß. Nature 395:612–615[CrossRef][Medline]
  55. Handschin C, Blaettler S, Roth A, Looser R, Oscarson M, Kaufmann MR, Podvinec M, Gnerre C, Meyer UA 2004 The evolution of drug-activated nuclear receptors: one ancestral gene diverged into two xenosensor genes in mammals. Nucl Recept 2:7[CrossRef][Medline]
  56. Dehal P, Satou Y, Campbell RK, Chapman J, Degnan B, De Tomaso A, Davidson B, Di Gregorio A, Gelpke M, Goodstein DM, Harafuji N, Hastings KE, Ho I, Hotta K, Huang W, Kawashima T, Lemaire P, Martinez D, Meinertzhagen IA, Necula S, Nonaka M, Putnam N, Rash S, Saiga H, Satake M, et al 2002 The draft genome of Ciona intestinalis: insights into vertebrate origins. Science 298:2157–2167[Abstract/Free Full Text]
  57. Bertrand S, Brunet F, Escriva H, Parmentier G, Laudet V, Robinson-Rechavi M 2004 Evolutionary genomics of nuclear receptors: from twenty-five ancestral genes to derived endocrine systems. Mol Biol Evol 21:1923–1937[Abstract/Free Full Text]
  58. Watkins RE, Davis-Searles PR, Lambert MH, Redinbo MR 2003 Coactivator binding promotes the specific interaction between ligand and the pregnane X receptor. J Mol Biol 331:815–828[CrossRef][Medline]
  59. Watkins RE, Noble SM, Redinbo MR 2002 Structural insights in the promiscuity and function of the human pregnane X receptor. Curr Opin Drug Discov Devel 5:150–158[Medline]
  60. Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, Rosenfeld MG, Willson TM, Glass CK, Milburn MV 1997 Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-{gamma}. Nature 395:137–143[CrossRef]
  61. Zhang J, Kuehl P, Green ED, Touchman JW, Watkins PB, Daly A, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Wrighton SA, Hancock M, Kim RB, Strom S, Thummel K, Russell CG, Hudson Jr JR, Schuetz EG, Boguski MS 2001 The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics 11:555–572[CrossRef][Medline]
  62. Hagenbuch B, Dawson P 2004 The sodium bile salt cotransporter family SLC10. Pflugers Arch 447:566–570[CrossRef][Medline]
  63. Burtis CA, Ashwood ER, eds. 1999 Tietz textbook of clinical chemistry. 3rd ed. Philadelphia: W.B. Saunders Co
  64. Ceryak S, Bouscarel B, Fromm H 1993 Comparative binding of bile acids to serum lipoproteins and albumin. J Lipid Res 34:1661–1674[Abstract]
  65. Cowen AE, Korman MG, Hofmann AF, Thomas PJ 1975 Metabolism of lithocholate in healthy man. III. Plasma disappearance of radioactivity after intravenous injection of labeled lithocholate and its derivatives. Gastroenterology 69:77–82[Medline]
  66. Rudman D, Kendall FE 1957 Bile acid content of human serum. II. The binding of cholanic acids by human plasma proteins. J Clin Invest 36:538–542[Medline]
  67. Kasbo J, Saleem M, Perwaiz S, Mignault D, Lamireau T, Tuchweber B, Yousef I 2002 Biliary, fecal and plasma deoxycholic acid in rabbit, hamster, guinea pig, and rat: comparative study and implication in colon cancer. Biol Pharm Bull 25:1381–1384[CrossRef][Medline]
  68. Stahl AM, Gillen CM, Takamata A, Nadel ER, Mack GW 2003 Reduced blood-to-tissue albumin movement after plasmapheresis. Shock 19:440–447[CrossRef][Medline]
  69. Lurie F, Jahr JS, Driessen B 2002 Changes in circulating blood and plasma volume after hemoglobin-based oxygen carrier infusion and additional infusion of colloid solutions. Am J Ther 9:425–430[CrossRef][Medline]
  70. Bromidge ES, Wells JW, Wight PAL 1985 Elevated bile acids in the plasma of laying hens fed rapeseed meal. Res Vet Sci 39:378–382[Medline]
  71. Yang Z 1997 PAML: a program package for phylogenetic analysis by maximum likelihood. Comput Appl Biosci 13:555–556[Medline]
  72. Yang Z, Nielsen R 2002 Codon-substitution models for detecting molecular adaptation at individual sites along specific lineages. Mol Biol Evol 19:908–917[Abstract/Free Full Text]
  73. Yang Z, Nielsen R, Goldman N, Pedersen AK 2000 Codon-substitution models for heterogeneous selection pressure at amino acid sites. Genetics 155:431–449[Abstract/Free Full Text]
  74. Anisimova M, Bielawski JP, Yang Z 2001 Accuracy and power of the likelihood ratio test in detecting adaptive molecular evolution. Mol Biol Evol 18:1585–1592[Abstract/Free Full Text]